US Drug Recall Register
Class III · Low risk Terminated Initiated Nov 8, 2013 (13 years ago)

Paclitaxel Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Package Insert- Missing text on the product insert in the "Clinical Studies" and "Specific Adverse Events" sections.

What was recalled

PACLITAXEL INJECTION, USP (semisynthetic); 300 mg/50 mL; (6 mg/mL); Multiple Dose Vial;(NDC 63323-763-50); Rx Only; Manufactured for APP Pharmaceuticals, LLC; Schaumburg, IL 60173; Made in India

Recalling firm
Fresenius Kabi USA, LLC
NDC code
63323-763-50
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-016-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Paclitaxel recalls

See all
Class II · Moderate risk Terminated

Paclitaxel Semi-Synthetic active pharmaceutical ingredient…

Reason Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Attix Pharmaceuticals D-829-2015
Class II · Moderate risk Terminated

Paclitaxel Injection

Reason The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Hospira Inc. D-1682-2012